Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02404415 · ClinicalTrials.gov registry record
The Vanderbilt Atrial Fibrillation Ablation Registry
A clinical trial of Atrial Fibrillation, sponsored by Vanderbilt University.
- Recruiting
- Registry status
- 3,000
- Enrollment target
- 1
- Study location
NCT02404415 is a study of Atrial Fibrillation that is actively recruiting participants, run by Vanderbilt University. The registered enrollment target is 3,000 participants, roughly in line with the 2,982-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target. The trial reports 1 study location across 1 state.
The verdict
NCT02404415, a study of Atrial Fibrillation, is actively recruiting participants, sponsored by Vanderbilt University.
- RECRUITING
- Registry status
- 3,000 participants
- Enrollment target
- 1
- Study location
Study Summary
The Vanderbilt Atrial Fibrillation Ablation registry (VAFAR) is a prospective clinical and genetic biorepository that systematically enrolls patients undergoing atrial fibrillation (AF) ablation. The registry was started in 2011 and has greater than 1000 AF ablation records with stored blood and DNA samples. The goals of VAFAR are to: 1) identify clinical, genetic, and serological predictors of response to AF ablation in order to improve patient selection, and 2) to provide a resource for translational research investigating the electrophysiologic mechanisms of AF pathogenesis.
Conditions Studied
Study Locations (1)
Tennessee
- Vanderbilt University Medical Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,000 participants |
| Start Date | 2011-10 |
| Est. Completion | 2028-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02404415
The ClinicalTrials.gov registry entry for NCT02404415 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 3,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 2,982-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target. The listed sponsor is Vanderbilt University, which has 430 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Atrial Fibrillation appearing as the primary indexed condition, and to 0 interventions.
NCT02404415 reports 1 study location spanning 1 distinct geographic area - top geographies include Tennessee.
Frequently Asked Questions
What is clinical trial NCT02404415 about?
NCT02404415 is a clinical study titled "The Vanderbilt Atrial Fibrillation Ablation Registry". The Vanderbilt Atrial Fibrillation Ablation registry (VAFAR) is a prospective clinical and genetic biorepository that systematically enrolls patients undergoing atrial fibrillation (AF) ablation. The registry was started in 2011 and has greater than 1000 AF ablation records with stored blood and DNA...
What is the current status of trial NCT02404415?
This trial is currently recruiting. The enrollment target is 3,000 participants. The study started on 2011-10. Estimated completion is 2028-10.
What conditions does trial NCT02404415 study?
This clinical trial studies the following conditions: Atrial Fibrillation.
Who is sponsoring clinical trial NCT02404415?
This trial is sponsored by Vanderbilt University, which has 430 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02404415 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atrial Fibrillation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
RECRUITING · Phase 2
-
Amiodarone for the Prevention of Atrial Fibrillation After Minimally Invasive Esophagectomy in Patients With Esophageal Cancer
RECRUITING · Phase 2
-
The Dynamics of Human Atrial Fibrillation
RECRUITING
-
Renal Denervation + PVI vs PVI Alone for Persistent AF
RECRUITING · NA
-
Pericardiotomy in Cardiac Surgery
RECRUITING · NA
-
CellFX® Nanosecond Pulsed Field Ablation (nsPFA)™ Cardiac Surgery Clamp System to Treat Atrial Fibrillation
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.